Researchers at the University of Bristol tested a new way to help people whose depression does not get better with normal pills. They used a medicine called tocilizumab, which is usually given to people with arthritis.
The study was small. Only 30 adults with moderate to severe depression took part. All of them had a little inflammation in their blood, which means their immune system was a bit over‑active.
Participants were split into two groups. One group received a single dose of tocilizumab; the other group got a harmless salt‑water injection (placebo). Over four weeks, researchers watched how the participants felt.
Even though the numbers were low, the group that got the arthritis drug showed more improvement. They felt less sad, less anxious, and had more energy. About half of them (54%) felt their depression lift enough to be called “remission,” compared with only 31% in the placebo group.
Scientists think the drug works by blocking a protein called interleukin‑6 (IL‑6). High levels of IL‑6 are often found in people with depression, suggesting the immune system can affect mood.
One of the researchers said this is one of the first studies to try immunotherapy for depression and the first to pick patients who show signs of inflammation. The goal is to match treatments to a person’s biology, giving the right medicine to the right patient.
The next step is a much larger trial. If those results are similar, doctors might one day have an extra tool – an immune‑targeting medicine – for patients whose depression doesn’t respond to ordinary antidepressants.